Entrada Therapeutics, Inc. (TRDA) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Join SI Premium – FREE
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q2 EPS of ($1.04), $0.22 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $2 million versus the consensus estimate of $9.65 million.
For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
- Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c
- Borr Drilling (BORR) Misses Q2 EPS by 69c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
